Eclipse Life Sciences Reports Positive Phase 2 Results for EC-104 in Diabetic Macular Edema

Eclipse Life Sciences' BETTIS-1 Phase 2 trial for EC-104, an extended-release corticosteroid implant for diabetic macular edema (DME), met its primary safety endpoint. Secondary results showed superior and durable improvements in visual acuity and central subfield thickness at 24 weeks compared to Ozurdex®. These findings are significant for DME patients who respond poorly to anti-VEGF therapies, addressing a substantial unmet medical need.